Literature DB >> 22093403

Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality.

Alicia Hernández-Torres1, Elisa García-Vázquez, Joaquín Gómez, Manuel Canteras, Joaquín Ruiz, Genoveva Yagüe.   

Abstract

BACKGROUND AND
OBJECTIVE: To analyse factors related to mortality and influence of antibiotic treatment on outcome in patients with nosocomial infection due to multidrug and carbapenem-resistant Acinetobacter baumannii (MDR-C AB). PATIENTS AND METHODS: Observational and prospective study of a cohort of adult patients with MDR-C AB infection. Data collection from clinical records was done according to a standard protocol (January 2007 through June 2008). Patients with MDR-C AB infection were identified by review of results of microbiology cultures from the hospital microbiology laboratory. Epidemiological and clinical variables and predictors of mortality were analysed.
RESULTS: 24 out of 101 cases were considered colonizations and 77 infections (27 bacteraemia); global mortality in infected patients was 49% (18 cases with bacteraemia and 20 with no bacteraemia). In the multivariate analysis, including the 77 cases of infection, the prognosis factors associated with mortality were age (OR 1.09; 95% CI 1.02-1.2), McCabe 1 (OR 33.98; 95% CI 4.33-266.85), bacteraemia (OR 9.89; 95% CI 1.13-86.13), inadequate empiric treatment (OR 16.7; 95% CI 2.15-129.79), and inadequate definitive treatment (OR 26.29; 95% CI 1.45-478.19). In the multivariate analysis including the 57 cases of infection with adequate definitive treatment, the prognosis factors associated with mortality were McCabe 1 (OR 24.08; 95% CI 3.67-157.96) and monotherapy versus combined treatment (OR 7.11; 95% CI 1.63-30.99).
CONCLUSIONS: Our cohort of patients with MDR-C AB infection is characterised by a very high mortality (49%); the severity of patients and inadequate treatment or monotherapy are statistically associated with mortality.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093403     DOI: 10.1016/j.medcli.2011.06.024

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  11 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

Review 2.  Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.

Authors:  P Poulikakos; G S Tansarli; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-16       Impact factor: 3.267

3.  Which Multidrug-Resitant Bacteria are Emerging in Patients with Hematological Malignancies?: One-Year Report.

Authors:  Habip Gedik; Funda Şimşek; Taner Yıldırmak; Arzu Kantürk; Demet Aydın; Naciye Demirel; Osman Yokuş; Deniz Arıca
Journal:  Indian J Hematol Blood Transfus       Date:  2014-05-14       Impact factor: 0.900

4.  Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.

Authors:  Samir Samal; Shakti B Samir; Shantanu K Patra; Arun Rath; Abhilash Dash; Biswajit Nayak; Diganta Mohanty
Journal:  Indian J Crit Care Med       Date:  2021-02

5.  Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.

Authors:  Ilker Inanc Balkan; Ayse Batirel; Oguz Karabay; Canan Agalar; Serife Akalin; Ozlem Alici; Emine Alp; Fatma Aybala Altay; Nilgun Altin; Ferhat Arslan; Turan Aslan; Nural Bekiroglu; Salih Cesur; Aygul Dogan Celik; Mustafa Dogan; Bulent Durdu; Fazilet Duygu; Aynur Engin; Derya Ozturk Engin; Ibak Gonen; Ertugrul Guclu; Tumer Guven; Cigdem Ataman Hatipoglu; Salih Hosoglu; Mustafa Kasim Karahocagil; Aysegul Ulu Kilic; Bahar Ormen; Davut Ozdemir; Serdar Ozer; Nefise Oztoprak; Nurbanu Sezak; Vedat Turhan; Nesrin Turker; Hava Yilmaz
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

6.  The impact of inadequate terminal disinfection on an outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit.

Authors:  Wei-Lun Liu; Hsueh-Wen Liang; Mei-Feng Lee; Hsin-Lan Lin; Yu-Hsiu Lin; Chi-Chung Chen; Ping-Chin Chang; Chih-Cheng Lai; Yin-Ching Chuang; Hung-Jen Tang
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

7.  Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: A retrospective multicenter study in Korea.

Authors:  Tark Kim; Eun Jung Lee; Seong Yeon Park; Shi Nae Yu; Yu Mi Lee; Ki-Ho Park; Se Yoon Park; Min Hyok Jeon; Eun Ju Choo; Tae Hyong Kim; Mi Suk Lee
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Beverlie Baquir; Andrew Tomaras; Justin I Montgomery; Usa Reilly; Elsa G Barbacci; Kristine Hujer; Robert A Bonomo; Lucia Fernandez; Robert E W Hancock; Mark D Adams; Samuel W French; Virgil S Buslon; Brad Spellberg
Journal:  MBio       Date:  2012-10-02       Impact factor: 7.867

9.  Carbapenemase Genes and Multidrug Resistance of Acinetobacter Baumannii: A Cross Sectional Study of Patients with Pneumonia in Southern Vietnam.

Authors:  Cuong Hoang Quoc; Thao Nguyen Thi Phuong; Hai Nguyen Duc; Trung Tran Le; Hang Tran Thi Thu; Si Nguyen Tuan; Lan Phan Trong
Journal:  Antibiotics (Basel)       Date:  2019-09-12

10.  Colistin-Resistant Acinetobacter Baumannii Bacteremia: A Serious Threat for Critically Ill Patients.

Authors:  Georgios Papathanakos; Ioannis Andrianopoulos; Athanasios Papathanasiou; Efthalia Priavali; Despoina Koulenti; Vasilios Koulouras
Journal:  Microorganisms       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.